Navigation Links
Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
Date:8/4/2008

EMERYVILLE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.1 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies CEO to Retire on December 31, 2008
2. Neurobiological Technologies Reports Third Quarter Financial Results
3. Neurobiological Technologies Sets Date for Third Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Sets Date for Research and Development Day
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... systems are increasingly being developed with Wi-Fi connectivity to reduce the amount of ... room to room. In addition, compact mobile devices including infusion pumps, heart and ...
(Date:5/23/2017)... ... May 23, 2017 , ... A recent survey conducted by the Weed ... to control weed in 12 categories of broadleaf crops, fruits and vegetables, while common ... the U.S. and Canada participated in the 2016 survey, the second conducted by WSSA. ...
(Date:5/23/2017)... Hong Kong (PRWEB) , ... May 22, 2017 ... ... the third year in a row in the Aragon Research Globe™ for Corporate ... that align with industry direction and market demand, and effectively perform against those ...
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq Technology, a world leader ... expansion to accommodate its rapid growth. , The renovations at the company’s headquarters ... the existing areas. The expansion includes, a state-of-the-art engineering facility, and a second ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):